Immunomodulatory Drugs in AL Amyloidosis | oneAMYLOIDOSISvoice
Scientific Articles

Immunomodulatory Drugs in AL Amyloidosis

key information

source: Critical Reviews in Oncology/Hematology

year: 2016

authors: Jelinek T, Kufova Z, Hajek R


Immunoglobulin light chain amyloidosis (AL amyloidosis) is indeed a rare plasma cell disorder, yet the most common of the systemic amyloidoses. The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients. Immunomodulatory drugs (IMiDs) are currently used in newly diagnosed patients as well as in salvage therapy in relapsed/refractory patients. 

IMiDs have a pleiotropic effect on malignant cells and the exact mechanism of their action has been described recently. Thalidomide is the most ancient representative, effective but toxic. Lenalidomide seems to be more effective, nevertheless the toxicity remains high, especially in patients with renal insufficiency. Pomalidomide is the newest IMiD used in this indication with a good balance between efficacy and tolerable toxicity and represents the most promising compound. This review is focused on the evaluation of all three representatives of IMiDs and their roles in the treatment of this malignant disorder.

organization: University Hospital Ostrava, Czech Republic; University of Ostrava, Czech Republic

DOI: 10.1016/j.critrevonc.2016.01.004

read more


The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.